ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets common cancer mutation in early trial
Disease control TerminatedThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Matched conditions: ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug LB4330 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…
Matched conditions: ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 16:51 UTC